2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1722

Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Abstract Number: 1723

Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice
Abstract Number: 1724

The Effect of Certolizumab Pegol on Skin Manifestations of Psoriatic Arthritis over 4 Years of Treatment
Abstract Number: 1725

Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Abstract Number: 1726

An Integrated Safety Data Analysis Across All Phase II and Phase III Clinical Programs for Ustekinumab in Psoriatic Arthritis, Crohn’s Disease, and Psoriasis
Abstract Number: 1727

Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Abstract Number: 1728

Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Abstract Number: 1729

Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
Abstract Number: 1730

Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Abstract Number: 1731

Disease Burden and Impact of Certolizumab Pegol Treatment on Workplace and Household Productivity Across Working Age Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis Patients
Abstract Number: 1732

Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice
Abstract Number: 1733

Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Abstract Number: 1734

Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients
Abstract Number: 1735

Canadian Humira Post-Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA): Interim Analysis
Abstract Number: 1736

Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].